Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

NASDAQ:TNXP - Nasdaq - US8902608475 - Common Stock - Currency: USD

9.17  -0.5 (-5.17%)

After market: 9.44 +0.27 (+2.94%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TNXP. TNXP was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of TNXP have multiple concerns. TNXP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TNXP had negative earnings in the past year.
In the past year TNXP has reported a negative cash flow from operations.
TNXP had negative earnings in each of the past 5 years.
In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

TNXP has a worse Return On Assets (-142.38%) than 83.66% of its industry peers.
Looking at the Return On Equity, with a value of -182.25%, TNXP is doing worse than 68.38% of the companies in the same industry.
Industry RankSector Rank
ROA -142.38%
ROE -182.25%
ROIC N/A
ROA(3y)-55.21%
ROA(5y)-86.34%
ROE(3y)-69.72%
ROE(5y)-119.89%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

With a decent Gross Margin value of 20.74%, TNXP is doing good in the industry, outperforming 74.42% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNXP has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, TNXP has more shares outstanding
The debt/assets ratio for TNXP is higher compared to a year ago.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -11.28, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
TNXP has a Altman-Z score of -11.28. This is in the lower half of the industry: TNXP underperforms 76.38% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that TNXP is not too dependend on debt financing.
TNXP has a worse Debt to Equity ratio (0.07) than 65.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -11.28
ROIC/WACCN/A
WACC9.39%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

TNXP has a Current Ratio of 3.33. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
TNXP has a worse Current ratio (3.33) than 60.39% of its industry peers.
A Quick Ratio of 2.78 indicates that TNXP has no problem at all paying its short term obligations.
TNXP has a Quick ratio of 2.78. This is in the lower half of the industry: TNXP underperforms 65.90% of its industry peers.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 2.78
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TNXP have decreased strongly by -450.70% in the last year.
The Revenue has grown by 182.98% in the past year. This is a very strong growth!
EPS 1Y (TTM)-450.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.72%
Revenue 1Y (TTM)182.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.26%

3.2 Future

Based on estimates for the next years, TNXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.36% on average per year.
Based on estimates for the next years, TNXP will show a very strong growth in Revenue. The Revenue will grow by 74.72% on average per year.
EPS Next Y-422.38%
EPS Next 2Y-188.96%
EPS Next 3Y19.36%
EPS Next 5YN/A
Revenue Next Year63.62%
Revenue Next 2Y42.72%
Revenue Next 3Y74.72%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -500M -1B -1.5B

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K -2K

4.3 Compensation for Growth

TNXP's earnings are expected to grow with 19.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-188.96%
EPS Next 3Y19.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (2/21/2025, 6:01:28 PM)

After market: 9.44 +0.27 (+2.94%)

9.17

-0.5 (-5.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners0.29%
Inst Owner Change1251.23%
Ins Owners0%
Ins Owner Change0%
Market Cap48.23M
Analysts82.5
Price TargetN/A
Short Float %N/A
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-192.57%
Min EPS beat(2)-477.45%
Max EPS beat(2)92.31%
EPS beat(4)3
Avg EPS beat(4)-70.42%
Min EPS beat(4)-477.45%
Max EPS beat(4)92.31%
EPS beat(8)5
Avg EPS beat(8)-33.3%
EPS beat(12)7
Avg EPS beat(12)-19.58%
EPS beat(16)8
Avg EPS beat(16)-16.63%
Revenue beat(2)0
Avg Revenue beat(2)-24.21%
Min Revenue beat(2)-38.15%
Max Revenue beat(2)-10.27%
Revenue beat(4)0
Avg Revenue beat(4)-21.93%
Min Revenue beat(4)-38.15%
Max Revenue beat(4)-3.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-72.22%
EPS NQ rev (1m)-9798.99%
EPS NQ rev (3m)-18626.1%
EPS NY rev (1m)-9900%
EPS NY rev (3m)-9726.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-60.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.27
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-1984.28
EYN/A
EPS(NY)-2303.16
Fwd EYN/A
FCF(TTM)-13.15
FCFYN/A
OCF(TTM)-13.05
OCFYN/A
SpS2.15
BVpS14.11
TBVpS14.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.38%
ROE -182.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.74%
FCFM N/A
ROA(3y)-55.21%
ROA(5y)-86.34%
ROE(3y)-69.72%
ROE(5y)-119.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.19%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 2.78
Altman-Z -11.28
F-Score4
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)24885.3%
Cap/Depr(5y)20651.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-450.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.72%
EPS Next Y-422.38%
EPS Next 2Y-188.96%
EPS Next 3Y19.36%
EPS Next 5YN/A
Revenue 1Y (TTM)182.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.26%
Revenue Next Year63.62%
Revenue Next 2Y42.72%
Revenue Next 3Y74.72%
Revenue Next 5YN/A
EBIT growth 1Y33.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.1%
OCF growth 3YN/A
OCF growth 5YN/A